cardiovascular research foundation

(Cardiovascular Research Foundation) The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation is a comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke.

(Cardiovascular Research Foundation) Results from the PROFI study indicate that the use of a proximal balloon occlusion in carotid artery stenting lead to fewer cerebral ischemic lesions -- a predictor of stroke -- than with the use of a filter.

Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

(Cardiovascular Research Foundation) Results of the PARTNER Cohort A QOL study demonstrate that transcatheter aortic valve replacement (TAVR) results in improved quality of life compared with surgical valve replacement, but only when performed via the transfemoral approach.

The results of the study were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

(The Medicines Company) Late breaking clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet, showed patients can be "bridged" from the time that their physicians stop their oral antiplatelet drugs until they undergo cardiac surgery.

Study results demonstrated cangrelor maintained target levels of platelet inhibition known to be associated with a low risk of thrombotic events, such as stent thrombosis, vs. placebo.

(Cardiovascular Research Foundation) Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation.

TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest research developments in interventional cardiovascular medicine.

Now in its 23rd year, it is the world's largest privately-run medical conference and attended by more than 10,000 participants each year.

TCT 2011 will be held Nov. 7-11 in San Francisco, Calif.

(Cardiovascular Research Foundation) Transcatheter Valve Therapies: An Advanced Scientific and Clinical Workshop (TVT) is a unique educational event, offering an in-depth review of the diagnostic and therapeutic options for the treatment of valvular heart disease.

(Cardiovascular Research Foundation) The Sixth International Conference on Cell Therapy for Cardiovascular Disease is a one-and-a-half day comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke.

This year’s conference will focus on commercialization aspects of the field, highlighting the status of molecular, cell and tissue products in addition to delivery systems.

(Cardiovascular Research Foundation) Lillian Feldshuh of Scarsdale, N.Y., an early recipient of a transcatheter aortic valve in 2006, received the Courageous Patient Award yesterday at the Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, D.C.

The procedure was a success and Feldshuh, who will turn 100 years in just 7 months, remains in good health.

(Cardiovascular Research Foundation) The 7th International Chronic Total Occlusion Summit is a two-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions.

(Cardiovascular Research Foundation) Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.